JNJ

192.83

-0.04%↓

ABT

128.28

-0.32%↓

MDT

96.41

+0.52%↑

VEEV

289.99

+0.39%↑

A

145.49

-0.36%↓

JNJ

192.83

-0.04%↓

ABT

128.28

-0.32%↓

MDT

96.41

+0.52%↑

VEEV

289.99

+0.39%↑

A

145.49

-0.36%↓

JNJ

192.83

-0.04%↓

ABT

128.28

-0.32%↓

MDT

96.41

+0.52%↑

VEEV

289.99

+0.39%↑

A

145.49

-0.36%↓

JNJ

192.83

-0.04%↓

ABT

128.28

-0.32%↓

MDT

96.41

+0.52%↑

VEEV

289.99

+0.39%↑

A

145.49

-0.36%↓

JNJ

192.83

-0.04%↓

ABT

128.28

-0.32%↓

MDT

96.41

+0.52%↑

VEEV

289.99

+0.39%↑

A

145.49

-0.36%↓

Search

Hologic Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

73.96 -0.3

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

73.93

Max

74.21

Pagrindiniai rodikliai

By Trading Economics

Pajamos

212M

195M

Pardavimai

19M

1B

P/E

Sektoriaus vid.

28.98

37.461

Pelnas, tenkantis vienai akcijai

1.08

Pelno marža

19.037

Darbuotojai

7,063

EBITDA

341M

334M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+7.44% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-03

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.3B

16B

Ankstesnė atidarymo kaina

74.26

Ankstesnė uždarymo kaina

73.96

Naujienos nuotaikos

By Acuity

26%

74%

49 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Hologic Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-21 13:20; UTC

Įsigijimai, susijungimai, perėmimai

Blackstone, TPG to Buy Hologic for Up to $18.3 Billion

2025-05-27 18:46; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

Hologic Shares Up Following Report of Buyout Offer From TPG, Blackstone

2025-10-21 16:36; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Hologic Seen as Prime Take-Private Candidate -- Market Talk

2025-10-21 13:05; UTC

Įsigijimai, susijungimai, perėmimai

Blackstone, TPG to Buy Hologic for Up to $18.3B

2025-10-21 12:50; UTC

Įsigijimai, susijungimai, perėmimai

Hologic Plans to File Form 10-K for Fiscal 2025 With the SEC in Late Nov >HOLX

2025-10-21 12:49; UTC

Įsigijimai, susijungimai, perėmimai

Hologic Does Not Intend to Provide Fincl Guidance for FY26 in Upcoming 4Q Results Release

2025-10-21 12:48; UTC

Įsigijimai, susijungimai, perėmimai

Hologic Merger Agreement Includes a 45-Day 'Go-Shop' Period >HOLX

2025-10-21 12:48; UTC

Įsigijimai, susijungimai, perėmimai

Hologic Will Continue to Operate Under the Hologic Name and Brand >HOLX

2025-10-21 12:48; UTC

Įsigijimai, susijungimai, perėmimai

Hologic Will Maintain Its Headquarters in Marlborough, Massachusetts >HOLX

2025-10-21 12:47; UTC

Įsigijimai, susijungimai, perėmimai

Blackstone's Private Equity Strategy for Individual Investors Is Also Expected to Invest as Part of Transaction

2025-10-21 12:46; UTC

Įsigijimai, susijungimai, perėmimai

Blackstone and TPG Secured Committed Financing From Citi, Bank of Amer, Barclays, Royal Bank of Canada and SMBC

2025-10-21 12:46; UTC

Įsigijimai, susijungimai, perėmimai

Blackstone and TPG Have Secured Committed Financing for the Transaction >HOLX

2025-10-21 12:45; UTC

Įsigijimai, susijungimai, perėmimai

Hologic: Transaction Includes Significant Minority Investments From Subsidiary of Abu Dhabi Investment Authority and an Affil of GIC >HOLX

2025-10-21 12:45; UTC

Įsigijimai, susijungimai, perėmimai

Hologic: Purchase Price Represents Premium of About 46% to Closing Price on May 23 >HOLX

2025-10-21 12:45; UTC

Įsigijimai, susijungimai, perėmimai

Hologic: Non-tradable CVR Would Be Issued to Holders at Closing and Paid Following Achievement of Certain Global Rev Goals for Breast Health Business in FY26, FY27

2025-10-21 12:44; UTC

Įsigijimai, susijungimai, perėmimai

Blackstone and TPG Will Acquire Hologic Shrs for $76/Shr in Cash Plus Non-Tradable CVR to Get Up to $3/Shr for Total of Up to $79/Shr in Cash >HOLX

2025-10-21 12:42; UTC

Įsigijimai, susijungimai, perėmimai

Hologic: Transaction Will Help Strengthen Leadership in Women's Health and Accelerate Growth >HOLX

2025-10-21 12:42; UTC

Įsigijimai, susijungimai, perėmimai

Hologic to Be Acquired by Funds Managed by Blackstone Deal and TPG in Deal With Enterprise Value of Up to $18.3 B >BX HOLX

2025-05-27 20:07; UTC

Įsigijimai, susijungimai, perėmimai

Hologic Stock Is Surging. Why Shares of the MedTech Company Are Up 14%. -- Barrons.com

2025-05-27 19:06; UTC

Įsigijimai, susijungimai, perėmimai

Hologic Stock Is Surging. Why Shares of the MedTech Company Are Up 14%. -- Barrons.com

2025-05-27 18:26; UTC

Įsigijimai, susijungimai, perėmimai

Hologic Stock Is Surging. Why Shares of the MedTech Company Are Up 19%. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Hologic Inc Prognozė

Kainos tikslas

By TipRanks

7.44% į viršų

12 mėnesių prognozė

Vidutinis 77.22 USD  7.44%

Aukščiausias 94 USD

Žemiausias 69 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Hologic Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

13 ratings

4

Pirkti

9

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

52.69 / 58.605Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Weak Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

49 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Hologic Inc

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat